Lakefront Biotherapeutics NVWBO:LKFT +0.79%60 Current Ratio is 30.48 as of Mar. 2026, which is 253% above its 10-year median of 8.63. GuruFocus rates WBO:LKFT with a GF Score™ of 60/100 and a GF Value™ of €104.25 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, Lakefront Biotherapeutics NV ranks better than 96.68% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lakefront Biotherapeutics NV's current ratio for the quarter that ended in Mar. 2026 was 30.48.
Lakefront Biotherapeutics NV has a current ratio of 30.48. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Lakefront Biotherapeutics NV's Current Ratio or its related term are showing as below:
WBO:LKFT'
s Current Ratio Range Over the Past 10 Years
Min: 4.49 Med: 8.63 Max: 30.48
Current: 30.48
During the past 13 years, Lakefront Biotherapeutics NV's highest Current Ratio was 30.48. The lowest was 4.49. And the median was 8.63.
WBO:LKFT's Current Ratio is ranked better than 96.68% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs WBO:LKFT: 30.48
Lakefront Biotherapeutics NV (WBO:LKFT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lakefront Biotherapeutics NV Current Ratio Related Terms
Lakefront Biotherapeutics NV Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:LKFT vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakefront Biotherapeutics NV Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lakefront Biotherapeutics NV's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakefront Biotherapeutics NV (WBO:LKFT) has a Current Ratio of 30.48 as of Mar. 2026. This is 253% above median its historical median of 8.63. Over the past decade, Lakefront Biotherapeutics NV's Current Ratio has ranged from 4.49 to 30.48. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #47 out of 1417 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Lakefront Biotherapeutics NV's Current Ratio too high?
Lakefront Biotherapeutics NV's current Current Ratio of 30.48 is 253% above median its 10-year median of 8.63. Over the past 10 years, this metric has ranged from a low of 4.49 to a high of 30.48. The Biotechnology industry median Current Ratio is 3.89. Lakefront Biotherapeutics NV's value of 30.48 is 683.5% above this industry median. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #47 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #47 out of 1417 companies for Current Ratio. This places Lakefront Biotherapeutics NV in the top 3% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Lakefront Biotherapeutics NV's value of 30.48 is 683.5% above this benchmark. Historically, Lakefront Biotherapeutics NV's own Current Ratio has ranged from 4.49 to 30.48 over the past decade. While the company's 10-year median is 8.63 vs. the industry median of 3.89, Lakefront Biotherapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lakefront Biotherapeutics NV's current Current Ratio of 30.48 is 683.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakefront Biotherapeutics NV's current Current Ratio is 30.48, which is 253% above median its own 10-year median of 8.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (WBO:LKFT) is currently considered Possible Value Trap. The stock's GF Value™ is €104.25, compared to a current price of €25.50 — trading 75.5% below its estimated fair value. The current Current Ratio is 30.48, which is 253% above median its 10-year median of 8.63 and 683.5% above the Biotechnology industry median of 3.89. Lakefront Biotherapeutics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (WBO:LKFT), the current Current Ratio is 30.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lakefront Biotherapeutics NV (WBO:LKFT) Overvalued in 2026?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued.
The current stock price of €25.50 is trading 75.5% below its estimated GF Value™ of €104.25.
GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.
Key valuation signals for WBO:LKFT:
Current Ratio: 30.48 (253% above median its 10-year median of 8.63)
GF Value™: €104.25 vs. price of €25.50 (75.5% below fair value)
Industry Position: 683.5% above the Biotechnology median (#47 of 1417)
No single metric tells the full story. See the WBO:LKFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
60GF Score
Get the complete analysis for WBO:LKFT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:LKFT has been successfully added to your 
